Cardiac troponins and left ventricular hypertrophy in hemodialysis patients

Clinical Laboratory

Volumn 54, Issue 5-6, 2008, Pages 145-152

  Petrović, Dejan ^a,c   Obrenović, Radmila ^b   Stojimirović, Biljana ^b  

^a CLINICAL CENTRE KRAGUJEVAC   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c Clinic of Urology and Nephrology   (Serbia)

Author keywords

Cardiac troponins; Hemodialysis; Left ventricular hypertrophy

Indexed keywords

TROPONIN I; TROPONIN T;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE WALL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT DURATION;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SURVIVAL ANALYSIS; TROPONIN I; TROPONIN T;

EID: 51049112439     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Parfrey PS. Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant 2000; 15(Suppl 5): 58-68.
2. Locatelli F, Bommer J, London G.M, Martin-Malo A, Wanner C, Yaqoob M, et al. Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. Nephrol Dial Transplant 2001; 16(3): 459-468.
3. Petrović D, Stojimirović B. 2005 Homocistein as risk-factor for cardiovascular complications in haemodialysis patients. In: Radenković S. (ed). Kardionefrologija 2. Niš, GIP "PUNTA", 2005. pp. 31-36. (Serbian)
4. London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant 2002; 17(Suppl 1): 29-36.
5. London GM. Cardiovascular Disease in Chronic Renal Failure: Pathophysiologic Aspects. Semin Dial 2003; 16(2): 85-94. (5)
6. Rigatto C, Parfrey PS. Uraemic Cardiomyopathy: an Overload Cardiomyopathy. J Clin Basic Cardiol 2001; 4(2): 93-95.
7. Herzog CA. Kidney disease in cardiology. Nephrol Dial Transplant 2007; 22(1): 43-46.
8. Sharma R, Gaze DC, Pellerin D, Mehta RL, Gregson H, Streather CP, et al. Cardiac structural and functional abnormalities in end stage renal disease patients with elevated cardiac troponin T. Heart 2006; 92(6): 804-809.
9. Ishii J, Nomura M, Okuma T, Minagawa T, Naruse H, Mori Y. Risk stratification using serum concentrations of cardiac troponin T in patients with end-stage renal disease on chronic maintenance dialysis. Clin Chim Acta 2001; 312(1): 69-79.
10. Jaffe AS, Babuin L, Apple FS. Biomarkers in Acute Cardiac Disease: The Present and the Future. J Am Coll Cardiol 2006; 48(1): 1-11.
11. Majkić-Singh N. Biochemical markers in diagnosing acute coronary syndrome. Jugoslov Med Biohem 2003; 22(4): 289-301. (Serbian)
12. Majkić-Singh N. The choice of biochemical markers in diagnosing acute coronary syndrome. Jugoslov Med Biohem 2005; 24(1): 1-13. (Serbian)
13. Wood GNI, Keevil B, Gupta J, Foley R, Bubtana A, McDowell G, Ackrill P. Serum troponin T measurement in patients with chronic renal impairment predicts survival and vascular disease: a 2 year prospective study. Nephrol Dial Transplant 2003; 18(8): 1610-1615.
14. Beciani M, Tedesco A, Violante A, Cipriano S, Azzarito M, Sturniolo A, Splendiani G. Cardiac troponin I (2nd generation assay) in chronic haemodialysis patients: prevalence and prognostic value. Nephrol Dial Transplant 2003; 18(5): 942-946.
15. Hussein M, Mooij J, Ronjouleh H, Shenawi OA. Cardiac troponin-1 and its prognostic significance in a dialysis population. Hemodialysis Int 2004; 8(4): 332-337.
16. Parfrey PS, Collingwood P, Foley RN, Bahrle A. Left ventricutar disorders detected by M-mode echocardiography in chronic uraemia. Nephrol Dial Transplant 1996; 11(7): 1328-1331.
17. Parfrey PS. Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant 2000; 15(Suppl 5): 58-68.
18. Middleton RJ, Parfrey PS, Foley RN. Left Ventricular Hypertrophy in the Renal Patient. J Am Soc Nephrol 2001; 12(5): 1079-1084.
19. Rigatto C, Parfrey PS, London GM. Cardiac hypertrophy in end-stage renal failure. In: Loscalzo J, London GM (eds). Cardiovascular Disease in End-stage Renal Failure. New York, The Oxford University Press, 2000. pp. 157-173.
20. McCullough P.A. Coronary Artery Disease. Clin J Am Soc Nephrol 2007; 2(3): 611-616.
21. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Malatino LS. Left ventricular mass monitoring in the follow-up of dialysis patients: Prognostic value of left ventricular hypertrophy progression. Kidney Int 2004; 65(4): 1492-8.
22. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995; 5(12): 2024-2031.
23. Kunz K, Dimitrov Y, Muller S, Chantrel F, Hannedouche T. Uraemic eardiomyopathy. Nephrol Dial Transplant 1998; 13 (Suppl 4): 39-43.
24. Scott B, Deman A, Peeters P, Van den Branden C, Stolear J-C, Camp GV, Verbeelen D. Cardiac troponin T and malonaldehyde modified plasma lipids in haemodialysis patients. Nephrol Dial Transplant 2003; 18(4): 737-742.
25. Conway B, McLaughlin M, Sharpe P, Harty J. Use of cardiac troponin T in diagnosis and prognosis of cardiac events in patients on chronic haemodialysis. Nephrol Dial Transplant 2005; 20(12): 2759-64.
26. Iliou MC, Fumeron C, Benoit MO, Tuppin P, Courvoisier CL, Calonge VM, Moatti N, Buisson C, Jacquot C. Factors associated with increased levels of cardiac troponins T and I in chronic haemodialysis patients: Chronic Haemodialysis and New Cardiac Markers Evaluation (CHANCE) study. Nephrol Dial Transplant 2001; 16(7): 1452-1458.
27. Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, Bonanno G, Fatuzzo P, Rapisarda F, Seminara G, Stancanelli B, Bellanuova I, Cataliotti A, Malatino LS. Diagnostic value of troponin T for alterations in left ventricular mass and function in dialysis patients. Kidney Int 2002; 62(5): 1884-1890.
28. Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, Bonanno G, Fatuzzo P, Rapisarda F, Seminara G, Stancanelli B, Bellanuova I, Cataliotti A, Malatino, LS. Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in haemodialysis patients. Am J Kidney Dis 2002; 40(1): 68-75.
29. Dierkes J, Domröse U, Westphal S, Ambrosch A, Bosselmann H-P, Neumann KE, et al. Cardiac Troponin T Predicts Mortality in Patients With End-Stage Renal Disease. Circulation 2000; 102(16): 1964-1975.
30. Boulier A, Jaussent I, Terrier N, Maurice F, Rivory J-P, Chalabi L, Boularan M, Delcourt C, Dupuy A-M, Canaud B, Cristol J-P. Measurement of circulating troponin Ic enhances the prognostic value of C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 2004; 19(9): 2313-2318.
31. Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive Value of Cardiac Troponin I and T for Subsequent Death in End-Stage Renal Disease. Circulation 2002; 106(23): 2941-2945.
32. Roberts MA, Fernando D, Macmillan N, Proimos G, Bach LA, Power DA, Ratnaike S, Ierino FL. Single and serial measurements of cardiac troponin I in asymptomatic patients on chronic haemodialysis. Clin Nephrol 2004; 61(1): 40-46.
33. Iliou MC, Fumeron C, Benoit MO, Tuppin P, Calonge VM, Moatti N, Buisson C, Jacquot C. Prognostic value of cardiac markers in ESRD: Chronic Haemodialysis and New Cardiac Markers Evaluation (CHA-NCE) study. Am J Kidney Dis 2003; 42(3): 513-523.
34. Nolan CR 2005 Strategies for Improving Long-Term Survival in Pa-tients with ESRD. J Am Soc Nephrol 2005; 16(11 Suppl 2): 120-127.
35. Johnson DW, Craven AM, Isbel NM. Modification of cardiovascular risk in haemodialysis patients: An evidence-based review. Haemodialysis Int 2007; 11(1): 1-14.